TScan Therapeutics is a biotechnology company that develops T-cell receptor therapies for the treatment of cancer. The company's platform uses a proprietary technology to identify and target cancer cells with high specificity. TScan's lead product candidate, TSC-100, is currently in Phase 1 clinical trials for the treatment of solid tumors. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.